BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 12480574)

  • 1. Characterization of focal hepatic lesions with SPIO-enhanced MRI.
    Zheng WW; Zhou KR; Chen ZW; Shen JZ; Chen CZ; Zhang SJ
    World J Gastroenterol; 2002 Feb; 8(1):82-6. PubMed ID: 11833077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal scanning concentration of MR imaging for tumor-bearing nude mice with SPIO-shRNA molecular probe.
    Zhang L; Yang X; Wen M
    Sci Rep; 2020 Oct; 10(1):18655. PubMed ID: 33122685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ternary hybrid nanocomposites for gene delivery and magnetic resonance imaging of hepatocellular carcinoma cells.
    Leung KC; Wong CH; Zhu XM; Lee SF; Sham KW; Lai JM; Chak CP; Wang YX; Cheng CH
    Quant Imaging Med Surg; 2013 Dec; 3(6):302-7. PubMed ID: 24404444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
    Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
    Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
    Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
    Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
    Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
    Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and characterization of hepatocellular carcinoma in rats with liver cirrhosis: diagnostic value of combined use of MR positive and negative contrast agents.
    Guo DM; Qiu TS; Bian J; Liu SF; Wang CZ
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):65-70. PubMed ID: 19208518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Focal liver lesions. A comparison between magnetic resonance under base conditions and after a superparamagentic contrast medium].
    Finazzo M; Midiri M; Gallo C; Bartolotta TV; Luca A
    Radiol Med; 1998 Jun; 95(6):599-607. PubMed ID: 9717542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Superparamagnetic iron oxide-enhanced magnetic resonance imaging of hepatocellular carcinoma in rats].
    Liu X; Xu YK; Huang QL; Wu YK
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1061-5. PubMed ID: 12480574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR imaging of hepatocellular carcinoma.
    Onaya H; Itai Y
    Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):757-68. PubMed ID: 11149678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR characterization of focal liver lesions: pearls and pitfalls.
    Siegelman ES; Chauhan A
    Magn Reson Imaging Clin N Am; 2014 Aug; 22(3):295-313. PubMed ID: 25086931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MR imaging and dynamic MR imaging].
    Yoshikawa K; Tobe K; Yoshioka N; Yoshida H
    Nihon Rinsho; 1996 May; 54(5):1255-62. PubMed ID: 8965347
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.